Editorial: Heterogeneity in breast cancer: clinical and therapeutic implications

被引：5
作者：
Carlino, Francesca [1 ]
Solinas, Cinzia [2 ]
Orditura, Michele [3 ]
Bisceglia, Maria Dezia [4 ]
Pellegrino, Benedetta [5 ]
Diana, Anna [6 ]
机构：
[1] Osped Ave Gratia Plena, Med Oncol Unit, San Felice A Cancello, Caserta, Italy
[2] Azienda Osped Univ AOU Cagliari Policlin Duilio Ca, Azienda Osped Univ AOU Cagliari Policlin Duilio Ca, Cagliari, Italy
[3] Med Oncol Unit, Aienda Osped Rilievo Nazl AORN St Anna & San Sebas, Caserta, Italy
[4] Aienda Osped Rilievo Nazl AORN St Anna & San Sebas, Aienda Ospedaliera Rilievo Nazl A O R N St Anna &, Caserta, Italy
[5] Univ Hosp Parma, Med Oncol & Breast Unit, Parma, Italy
[6] Osped Mare, Med Oncol Unit, Naples, Italy
来源：
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词：
breast cancer; heterogeneity; molecular mechanisms; drug resistance; emerging technologies;
D O I：
10.3389/fonc.2024.1321654
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 19 条
[1]   Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives [J].
Agostinetto, Elisa ;
Montemurro, Filippo ;
Puglisi, Fabio ;
Criscitiello, Carmen ;
Bianchini, Giampaolo ;
Del Mastro, Lucia ;
Introna, Martino ;
Tondini, Carlo ;
Santoro, Armando ;
Zambelli, Alberto .
CANCERS, 2022, 14 (09)
[2]   Hereditary Breast Cancer: The Era of New Susceptibility Genes [J].
Apostolou, Paraskevi ;
Fostira, Florentia .
BIOMED RESEARCH INTERNATIONAL, 2013, 2013
[3]   The effect of environment on breast cancer risk [J].
Coyle, YM .
BREAST CANCER RESEARCH AND TREATMENT, 2004, 84 (03) :273-288
[4]   Should triple-positive breast cancer be recognized as a distinct subtype? [J].
Dieci, Maria Vittoria ;
Guarneri, Valentina .
EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (12) :1011-1014
[5]   Male breast cancer: a disease distinct from female breast cancer [J].
Gucalp, Ayca ;
Traina, Tiffany A. ;
Eisner, Joel R. ;
Parker, Joel S. ;
Selitsky, Sara R. ;
Park, Ben H. ;
Elias, Anthony D. ;
Baskin-Bey, Edwina S. ;
Cardoso, Fatima .
BREAST CANCER RESEARCH AND TREATMENT, 2019, 173 (01) :37-48
[6]   Breast cancer heterogeneity and its implication in personalized precision therapy [J].
Guo, Liantao ;
Kong, Deguang ;
Liu, Jianhua ;
Zhan, Ling ;
Luo, Lan ;
Zheng, Weijie ;
Zheng, Qingyuan ;
Chen, Chuang ;
Sun, Shengrong .
EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2023, 12 (01)
[7]   Second primary malignancies in patients with male breast cancer [J].
Hemminki, K ;
Scélo, G ;
Boffetta, P ;
Mellemkjaer, L ;
Tracey, E ;
Andersen, A ;
Brewster, DH ;
Pukkala, E ;
McBride, M ;
Kliewer, EV ;
Chia, KS ;
Pompe-Kirn, V ;
Martos, C ;
Jonasson, JG ;
Li, X ;
Brennan, P .
BRITISH JOURNAL OF CANCER, 2005, 92 (07) :1288-1292
[8]   How to build and interpret a nomogram for cancer prognosis [J].
Iasonos, Alexia ;
Schrag, Deborah ;
Raj, Ganesh V. ;
Panageas, Katherine S. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (08) :1364-1370
[9]   Phyllodes Tumor of the Breast: Ultrasound-Pathology Correlation [J].
Kalambo, Megan ;
Adrada, Beatriz E. ;
Adeyefa, Modupe M. ;
Krishnamurthy, Savitri ;
Hess, Ken ;
Carkaci, Selin ;
Whitman, Gary J. .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2018, 210 (04) :W173-W179
[10]   Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer [J].
Li, Yunhai ;
Yang, Dejuan ;
Yin, Xuedong ;
Zhang, Xiang ;
Huang, Jiefeng ;
Wu, Yusheng ;
Wang, Mengxue ;
Yi, Zhiying ;
Li, Hongyuan ;
Li, Hongzhong ;
Ren, Guosheng .
JAMA NETWORK OPEN, 2020, 3 (01) :E1918160
12